I

    Incyte Corporation (INCY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $123.22
    -1.15 (-0.92%)

    Market Cap: $25.21B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    +16.77%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-3.47
    Range$-4.16 - $-2.34
    16 analysts
    EPS Revisions
    3
    0
    7d
    0
    8
    30d
    EPS Estimate Drift
    90d ago$2.00+157.6%
    60d ago$1.56+144.8%
    30d ago$-3.49-0.5%
    7d ago$-3.39+2.3%
    Current$-3.47
    Revenue Consensus
    $1.5B
    Range$1.4B - $1.5B
    19 analysts
    Dec 31, 2026
    EPS Consensus$3.47
    Range$2.70 - $4.41
    18 analysts
    Revenue Consensus
    $1.8B
    Range$1.7B - $1.8B
    22 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.47---
    Sep 26EST
    		-$-3.47---
    Jun 26
    		$2.80$1.76+59.09%Beat+78.3%
    Mar 26
    		$1.81$1.34+35.07%Beat+56.0%
    Dec 25
    		$1.80$1.92-6.25%Miss+25.9%
    Sep 25
    		$2.26$1.64+37.80%Beat+111.2%
    Jun 25
    		$1.57$1.47+6.80%Beat+186.3%
    Mar 25
    		$1.16$1.03+12.62%Beat+81.2%
    Dec 24
    		$1.43$1.55-7.74%Miss+34.9%
    Sep 24
    		$1.07$1.09-1.83%Miss-2.7%
    Jun 24
    		$-1.82$1.11-263.96%Miss-283.8%
    Mar 24
    		$0.64$0.83-22.89%Miss+73.0%
    Dec 23
    		$1.06$1.15-7.83%Miss+71.0%
    Sep 23
    		$1.10$1.07+2.80%Beat+83.3%
    Jun 23
    		$0.99$0.87+13.79%Beat-2.0%
    Mar 23
    		$0.37$0.74-50.00%Miss-32.7%
    Dec 22
    		$0.62$0.57+8.77%Beat+520.0%
    Sep 22
    		$0.60$0.71-15.49%Miss-49.2%
    Jun 22
    		$1.01$0.75+34.67%Beat+26.2%
    Mar 22
    		$0.55$0.69-20.29%Miss-17.9%
    Dec 21
    		$0.10N/A-88.51%Miss-89.2%
    Sep 21
    		$1.18$0.76+55.26%Beat+413.0%
    Jun 21
    		$0.80$0.74+8.11%Beat-35.5%
    Mar 21
    		$0.67$0.64+4.69%Beat+123.4%
    Dec 20
    		$0.93$0.77+20.78%Beat+43.1%
    Sep 20
    		$0.23N/A-69.74%Miss-72.0%
    Jun 20
    		$1.24$0.86+44.19%Beat+65.3%
    Mar 20
    		$-2.86$-2.80-2.14%Miss-561.3%
    Dec 19
    		$0.65$0.58+12.07%Beat+62.5%
    Sep 19
    		$0.82$0.64+28.13%Beat+115.8%
    Jun 19
    		$0.75$0.50+50.00%Beat+188.5%
    Mar 19
    		$0.62$0.41+51.22%Beat+6300.0%
    Dec 18
    		$0.40$0.46-13.04%Miss+156.3%
    Sep 18
    		$0.38$0.41-7.32%Miss+123.5%
    Jun 18
    		$0.26$0.22+18.18%Beat+533.3%
    Mar 18
    		$-0.01N/A-108.33%Miss+99.0%
    Dec 17
    		$-0.71$-0.45-57.78%Miss-1520.0%
    Sep 17
    		$0.17$0.06+183.33%Beat-10.5%
    Jun 17
    		$-0.06$-0.04-50.00%Miss-
    Mar 17
    		$-0.96$-0.88-9.09%Miss-
    Dec 16
    		$0.05N/A-64.29%Miss-
    Sep 16
    		$0.19$0.02+850.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio14.21EV/EBITDA10.34x
    Price/FCF12.86xFCF Yield7.78%
    Profitability
    Profit Margin27.70%Operating Margin41.90%
    ROE30.70%ROIC23.07%
    Financial Health
    Debt/Equity0.01xInterest Coverage772.97x
    Current Ratio4.59xQuick Ratio4.51x
    Trading Statistics
    Beta0.77Avg Volume1.33M
    52-Week High$132.6052-Week Low$81.09

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$126.81
    SMA 20$123.75
    SMA 50$119.12
    SMA 200$104.29
    EMA 10$125.61
    EMA 20$124.13
    EMA 50$118.71
    EMA 200$104.33

    MACD

    Line: 2.31Signal: 2.71Hist: -0.40

    ADX

    ADX: 21.8+DI: 26.3-DI: 24.9

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down32.0
    PSAR$130.80

    Bollinger Bands

    Upper Band$130.99
    Lower Band$116.51
    %B Position1170%(Upper)
    Band Width0.46

    RSI (14-Day)

    Neutral
    50.8

    Momentum Oscillators

    Stoch %K57.0
    Stoch %D69.9
    Williams %R-57.3
    ROC (10d)-0.2%
    Momentum-0.28
    CCI (20d)-13.6
    MFI (14d)49.6

    Volatility Measures

    ATR (14d)$3.44(2.8%)
    StdDev (20d)3.62
    Hist Vol24.5%(Moderate)

    Volume Flow

    VWAP$122.94
    OBV67.5M
    AD Line41.5M
    CMF (20d)0.151

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio1.1x
    VWMA (20d)$123.26

    Pivot Points

    R3$131.71
    R2$129.72
    R1$127.05
    Pivot Point$125.06
    S1$122.39
    S2$120.40
    S3$117.73

    Advanced Oscillators

    TSI19.37
    Ultimate Osc54.2
    KST60.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.67B$1.27B$1.51B$1.37B$1.22B$1.05B$1.18B$1.14B$1.04B$880.89M$1.01B$919.02M
    Cost of Revenue$104.96M$104.52M$121.17M$99.00M$78.77M$73.19M$88.48M$85.99M$76.63M$60.96M$69.75M$60.09M
    Gross Profit$1.57B$1.17B$1.39B$1.27B$1.14B$979.71M$1.09B$1.05B$967.13M$819.93M$943.59M$858.93M
    Operating Expenses$871.18M$867.04M$1.05B$823.46M$606.45M$774.54M$788.70M$905.79M$1.45B$728.03M$756.32M$644.23M
    R&D$516.95M$515.90M$611.37M$506.58M$494.92M$437.28M$466.03M$573.17M$1.14B$429.26M$444.49M$375.71M
    SG&A$351.74M$328.09M$390.41M$329.08M$331.02M$325.69M$326.71M$309.21M$305.98M$300.26M$288.23M$267.89M
    Operating Income$697.90M$301.12M$335.86M$443.52M$530.31M$205.17M$301.51M$146.09M$-478,130,000$91.90M$187.27M$214.71M
    Interest Income$47.92M$40.28M$49.00M$35.34M$20.98M$21.59M$11.02M$6.28M$80.72M$146.72M$192.47M$-26,654,000
    Interest Expense$582,000$569,000$582,000$592,000$594,000$660,000$419,000$774,000$657,000$430,000$804,000$623,000
    Income Before Tax$751.51M$343.60M$389.94M$482.31M$558.01M$234.19M$313.72M$156.52M$-389,777,000$236.16M$270.96M$233.80M
    Income Tax Expense$165.91M$40.27M$90.66M$58.14M$153.01M$75.99M$112.51M$50.07M$54.82M$66.61M$69.88M$62.53M
    Net Income$585.61M$303.33M$299.28M$424.17M$405.00M$158.20M$201.21M$106.46M$-444,601,000$169.55M$201.08M$171.27M
    EBITDA$730.65M$327.69M$365.50M$471.58M$560.54M$235.63M$325.86M$173.53M$-447,789,000$111.82M$101.05M$282.47M
    EBIT$704.17M$303.89M$341.52M$447.56M$537.62M$213.26M$303.13M$151.01M$-469,837,000$89.87M$79.29M$261.08M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    Incyte’s Earnings: Strong Growth Amid Market Overlook

    INCY generates $1.17B annual FCF with 93% gross margins and zero leverage, yet trades at 15.6x earnings. Reverse-DCF implies ~0% growth priced in. Quality Score 100/100 with ROIC 25.4%, Piotroski 8/9, interest coverage 702x, and $3.6B cash. This is fortress-grade biotech. Q4 revenue crushed estimates by 11% ($1.51B vs $1.35B). Full year $5.14B, up 21%. Core business ex-Jakafi grew 53% to $1.26B. Replacement revenue already $1.26B and guided to grow 30% in 2026. Management targets $3-4B core ex-Jakafi by 2030, turning the patent cliff into a slope. Post-earnings pullback breached first buy zone. Three tranches: current levels near $100, $96-$99 (channel support), $88-$92 (200-day defense). Blended fair value ~$155 implies ~55% upside. Four product launches on deck late 2026/early 2027: Jakafi XR, Opzelura moderate AD, Monjuvi sBLA, Povorcitinib.

    Unknown Author
    •
    2/11/26
    •
    129
    Biotech
    Healthcare Stocks
    Also mentions:
    NVS
    LLY
    REGN
    GILD

    News

    Incyte (INCY) Earnings History & Trends

    This article provides a detailed overview of Incyte (INCY) stock's earnings history and trends, including EPS and revenue performance against Street estimates. It highlights the company's 80% EPS beat rate and average EPS surprise of +16.84%, along with quarter-by-quarter financial data and post-earnings stock performance comparisons to the S&P 500.

    24/7 Wall St.•8/29/26•
    Bullish

    Incyte Corp. stock underperforms Friday when compared to competitors

    Incyte Corp. (INCY) shares fell 2.64% on Friday, closing at $124.37, underperforming its competitors and the broader market. This marks the stock's third consecutive day of losses, as the S&P 500 Index and Dow Jones Industrial Average also experienced declines.

    MarketWatch•8/28/26•
    Bearish

    Incyte (NASDAQ: INCY) HR chief holds 10,993 shares after tax withholding

    Incyte's EVP of Human Resources, Ramitpal K. Basi, had 504 shares of common stock withheld for tax obligations on August 25, 2026, stemming from the settlement of previously granted restricted stock units. After this transaction, Basi directly holds 10,993 shares, which includes 9,871 unvested restricted stock unit shares. The transaction price for the withheld shares was $129.72 per share.

    Stock Titan•8/27/26•
    Neutral

    Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?

    Incyte (INCY) shares have risen 0.8% since its last earnings report, underperforming the S&P 500. The company reported strong Q2 2026 results with earnings and revenues beating estimates, driven by sales of Jakafi and Opzelura, leading to raised 2026 guidance. However, analyst estimates have trended downward, and the stock currently holds a Zacks Rank #3 (Hold).

    Yahoo Finance•8/27/26•
    Bullish

    Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience

    Incyte (NASDAQ:INCY) has met both Mark Minervini's Trend Template and High Growth Momentum screens, indicating strong technical and fundamental performance. While the stock demonstrates robust growth in EPS and revenue, and is in a confirmed uptrend, its current setup score suggests patience is required for an optimal entry point due to recent price volatility. Investors are advised to wait for consolidation before considering a buy.

    ChartMill•8/27/26•
    Bullish

    Frequently Asked Questions About INCY

    Does INCY pay dividends?
    Incyte Corporation (INCY) does not currently pay a regular dividend.
    What is INCY's P/E ratio?
    Incyte Corporation has a price-to-earnings (P/E) ratio of 14.21.
    What is INCY's market cap?
    Incyte Corporation (INCY) has a market capitalization of $25.21B with a current stock price of $123.22.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In